Kylie Hill1,2, L W Cindy Ng3,4, Nola Cecins5, Vittoria R Formico6, Vinicius Cavalheri3,7, Sue C Jenkins3,7,5. 1. School of Physiotherapy and Exercise Science, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, WA, 6845, Australia. K.Hill@curtin.edu.au. 2. Institute for Respiratory Health, Sir Charles Gairdner Hospital, Perth, WA, Australia. K.Hill@curtin.edu.au. 3. School of Physiotherapy and Exercise Science, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, WA, 6845, Australia. 4. Physiotherapy Department, Singapore General Hospital, Singapore, Singapore. 5. Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, WA, Australia. 6. Physiotherapy Department, Faculdade de Ciências E Tecnologia, Universidade Estadual Paulista (UNESP), Presidente Prudente, Brazil. 7. Institute for Respiratory Health, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Abstract
PURPOSE: To determine the effects of providing a wheeled walker (WW) for use in the home and community, on daily physical activity (PA) and sedentary time (ST) in people with chronic obstructive pulmonary disease (COPD). METHODS: A randomised cross-over study in which participants with COPD characterised by a 6-min walk distance ≤ 450 m, who had recently finished pulmonary rehabilitation, completed two 5-week phases. During one phase, participants were provided a WW to use, whereas during the other phase, the WW was not available. The order of the phases was randomised. For the final week of each phase, measures of PA and ST were collected using wearable devices and health-related quality of life was measured using the Chronic Respiratory Disease Questionnaire (CRDQ). Wheeled walker use was also measured using an odometer attached to the device. RESULTS:17 participants [FEV1 = median (interquartile range) 33 (25) % pred; ten males] aged mean (SD) 73 (9) years completed the study. Comparing the data collected when the WW was not available for use, the daily step count was greater (mean difference [MD] 707 steps/day (95% confidence interval [CI] 75 to 1340) and participants tended to report less dyspnoea during daily life (MD 0.5 points per item, 95% CI - 0.1 to 1.0) when WW was available. No differences were observed for ST, upright time or stepping time. The WW was used over 4504 m/week (95% CI 2746 to 6262). CONCLUSION: These data demonstrated that, when provided to selected patients with COPD, WWs increased daily step count. CLINICAL TRIAL REGISTRATION NUMBER: ACTRN12609000332224.
RCT Entities:
PURPOSE: To determine the effects of providing a wheeled walker (WW) for use in the home and community, on daily physical activity (PA) and sedentary time (ST) in people with chronic obstructive pulmonary disease (COPD). METHODS: A randomised cross-over study in which participants with COPD characterised by a 6-min walk distance ≤ 450 m, who had recently finished pulmonary rehabilitation, completed two 5-week phases. During one phase, participants were provided a WW to use, whereas during the other phase, the WW was not available. The order of the phases was randomised. For the final week of each phase, measures of PA and ST were collected using wearable devices and health-related quality of life was measured using the Chronic Respiratory Disease Questionnaire (CRDQ). Wheeled walker use was also measured using an odometer attached to the device. RESULTS: 17 participants [FEV1 = median (interquartile range) 33 (25) % pred; ten males] aged mean (SD) 73 (9) years completed the study. Comparing the data collected when the WW was not available for use, the daily step count was greater (mean difference [MD] 707 steps/day (95% confidence interval [CI] 75 to 1340) and participants tended to report less dyspnoea during daily life (MD 0.5 points per item, 95% CI - 0.1 to 1.0) when WW was available. No differences were observed for ST, upright time or stepping time. The WW was used over 4504 m/week (95% CI 2746 to 6262). CONCLUSION: These data demonstrated that, when provided to selected patients with COPD, WWs increased daily step count. CLINICAL TRIAL REGISTRATION NUMBER: ACTRN12609000332224.
Authors: M E Lachman; J Howland; S Tennstedt; A Jette; S Assmann; E W Peterson Journal: J Gerontol B Psychol Sci Soc Sci Date: 1998-01 Impact factor: 4.077
Authors: Kylie Hill; Thomas E Dolmage; Lynda J Woon; Dina Brooks; Roger S Goldstein Journal: Arch Phys Med Rehabil Date: 2012-03-29 Impact factor: 3.966
Authors: Heleen Demeyer; Chris Burtin; Miek Hornikx; Carlos Augusto Camillo; Hans Van Remoortel; Daniel Langer; Wim Janssens; Thierry Troosters Journal: PLoS One Date: 2016-04-28 Impact factor: 3.240